1. anchor on January 3, 2011 9:57 AM writes...

Happy New Year to all....here are my crystal ball projections for 2011 and it is not a happy one. Jobs will be short in supply for the pharmaceutical industry (people already in the job block plus more will be added to the job pool). That said, there will be token job creations in the USA. More jobs are likely to be created in China and India with the former taking lion’s share. ACS/C&E News as usual will project a very optimistic scenario for the chemists. Overall the economy of the US will be just fine (but not for pharma industry) with jobless recovery and we have a huge pit to climb. By the way, the patent expiry of Lipitor will have a dramatic impact on Pfizer not into 2012 but I say here in 2011 and soon! As for Merck...Hmm.

2. cancer_man on January 3, 2011 10:16 AM writes...

David Sinclair says that he knows the important protein that is needed to act with resvertarol and the GSK compounds - what the Pfizer study missed.

Prediction: I think he'll be right and one of the GSK compounds will be seen as a breakthrough this year or in 2012.

3. Biosensorist on January 3, 2011 1:36 PM writes...

@ #2 - At this point do you believe anything Sinclair says? If so I have a bridge...

4. Ed on January 3, 2011 4:39 PM writes...

Astrazeneca look to have a tough year coming up, 3 late stage failures in December plus delay in introduction of Brilinta does not add up to a promising next few months.

5. Eduardo on January 3, 2011 10:29 PM writes...

Lilly (my former employer) is shaping up for a nasty 2011. Top seller Zyprexa, about a quarter of sales, goes off patent in the Spring. The company has laid nothing but R&D goose eggs in recent years, so it's going to be a lean few years as they drive in slow motion off a patent cliff from 2011-2014.

6. cancer_man on January 4, 2011 12:13 AM writes...

@biosensorist

By coincidence, I am in the market for a bridge, preferably in the Brooklyn area.

I still can't figure out why so many here think Sinclair is a lying fraud. That's always possible, but where is the evidence for such a damning charge? His study did without information on normal mice, but that happens all the time with studies.

I guess we'll know soon enough if his necessary protein argument is correct.

7. Another Comment on January 4, 2011 3:39 AM writes...

I suspect that Abbott will buy a few more companies. I think it has been about 5 or 6 maybe more a year for the last while... just a thought

8. Nick K on January 5, 2011 6:16 AM writes...

How many times have we heard that the floor of the Great Pharma Recession had been reached and that the only way was up? I predict that 2011 will be no different, and that the rot will continue.

9. Anonymous on January 9, 2011 1:33 PM writes...

I predict that Pfizer will buy some stuff.

And sack a few more......